Kineta, Inc. (KA) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Kineta, Inc. (KA) Healthcare & Pipeline Overview

Kineta, Inc. is a clinical-stage biotechnology company specializing in immunotherapies for oncology, neuroscience, and biodefense. With strategic partnerships including Pfizer and Genentech, Kineta aims to develop innovative treatments. The company operates in the competitive biotechnology sector, focusing on novel therapeutic approaches.

What Is the Investment Thesis for KA?

Kineta, Inc. presents a high-risk, high-reward investment opportunity typical of clinical-stage biotechnology companies. The company's focus on immunotherapies in oncology, neuroscience, and biodefense offers potential for significant growth, driven by unmet medical needs and strategic partnerships. Key value drivers include the advancement of its clinical pipeline, successful completion of clinical trials, and potential for licensing or acquisition by larger pharmaceutical companies. The company's gross margin of 162.9% indicates strong potential profitability if products reach the market. However, the company's negative profit margin of -76.3% reflects the high costs associated with research and development. Investors should closely monitor clinical trial results and partnership developments as key catalysts. The company's small market capitalization of $7.05M makes it susceptible to volatility and dilution.

Based on FMP financials and quantitative analysis

KA Key Highlights

• Gross Margin of 162.9% indicates potential for high profitability upon successful commercialization of products.
• Strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. provide access to resources and expertise.
• Focus on immunotherapies in oncology, neuroscience, and biodefense targets areas with significant unmet medical needs.
• Clinical-stage pipeline offers potential for value creation through successful clinical trial outcomes and regulatory approvals.
• Market Cap of $7.05M reflects the company's early stage and potential for growth, but also indicates higher risk.

Who Are KA's Competitors?

KA is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KA's Key Strengths?

• Strategic partnerships with major pharmaceutical companies.
• Focus on innovative immunotherapies.
• Potential for high gross margins.
• Diversified pipeline across oncology, neuroscience, and biodefense.

What Are KA's Weaknesses?

• Limited financial resources.
• Dependence on partnerships for funding and development.
• High risk of clinical trial failures.
• Small number of employees.

What Could Drive KA Stock Higher?

• Clinical trial results for lead immunotherapy candidates in oncology.
• Announcement of new strategic partnerships or collaborations.
• Continued advancement of preclinical programs in neuroscience and biodefense.
• Government funding opportunities for biodefense research.

What Are the Key Risks for KA?

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures and regulatory setbacks.
• Competition from larger pharmaceutical companies with greater resources.
• Dependence on external funding and partnerships.
• Intellectual property challenges and patent disputes.

What Are the Growth Opportunities for KA?

• Expansion of Oncology Pipeline: Kineta has the opportunity to expand its oncology pipeline by developing new immunotherapies targeting specific cancer types. Kineta can leverage its expertise in immunotherapy to develop novel treatments that address unmet needs in cancer care. Successful clinical trials and regulatory approvals in this area could significantly increase the company's value.
• Advancement of Neuroscience Programs: Kineta's neuroscience programs offer significant growth potential by addressing neurological disorders with limited treatment options. The market for neurological disorder treatments is projected to grow substantially, driven by an aging population and increasing prevalence of conditions such as Alzheimer's disease and Parkinson's disease. Kineta can capitalize on this opportunity by advancing its preclinical and clinical programs in neuroscience, potentially leading to breakthrough therapies.
• Development of Biodefense Solutions: Kineta's focus on biodefense provides a unique growth opportunity by developing immunotherapies to protect against biological threats. Government funding for biodefense research and development is increasing, driven by concerns about bioterrorism and emerging infectious diseases. Kineta can leverage its expertise in immunology to develop countermeasures against biological agents, potentially securing government contracts and partnerships.
• Strategic Partnerships and Collaborations: Kineta can drive growth through strategic partnerships and collaborations with pharmaceutical companies, research institutions, and government agencies. These partnerships can provide access to funding, expertise, and resources to accelerate the development and commercialization of its therapeutic candidates. Kineta's existing partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. demonstrate its ability to attract and maintain valuable collaborations.
• Licensing and Acquisition Opportunities: Kineta's pipeline of immunotherapies represents attractive licensing and acquisition opportunities for larger pharmaceutical companies seeking to expand their product portfolios. Successful clinical trial results and regulatory approvals can significantly increase the value of Kineta's assets, making them attractive targets for acquisition. Kineta can actively pursue licensing agreements and strategic partnerships to monetize its intellectual property and generate revenue.

What Opportunities Does KA Have?

• Expansion into new therapeutic areas.
• Securing government contracts for biodefense solutions.
• Licensing or acquisition of its assets by larger companies.
• Advancement of clinical pipeline through successful trials.

What Threats Does KA Face?

• Competition from larger pharmaceutical companies.
• Regulatory hurdles and approval delays.
• Patent challenges and intellectual property disputes.
• Economic downturn affecting research funding.

What Are KA's Competitive Advantages?

• Proprietary immunotherapy technologies.
• Strategic partnerships with leading pharmaceutical companies.
• Focus on niche therapeutic areas with unmet needs.
• Expertise in immunology and drug development.

What Does KA Do?

Kineta, Inc., founded in 2007 and based in Seattle, Washington, is a clinical-stage biotechnology company dedicated to developing innovative immunotherapies. Originally named Lecura, Inc., the company rebranded to Kineta to reflect its focus on kinetic approaches to modulating the immune system. Kineta targets significant unmet medical needs in oncology, neuroscience, and biodefense. Its core strategy involves creating first-in-class immunotherapies designed to treat diseases with substantial market potential. Kineta collaborates with private, government, and industry partners to advance its research and development efforts. The company has established strategic partnerships with leading organizations such as Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd., leveraging their expertise and resources to accelerate the development and commercialization of its therapeutic candidates. Kineta's pipeline includes programs focused on modulating immune responses to combat cancer, neurological disorders, and biodefense threats. The company's approach combines innovative science with strategic collaborations to create value and address critical healthcare challenges.

What Products and Services Does KA Offer?

• Develops immunotherapies for oncology.
• Creates treatments for neuroscience disorders.
• Researches and develops biodefense solutions.
• Partners with private, government, and industry organizations.
• Focuses on first-in-class immunotherapies.
• Conducts preclinical and clinical research.
• Aims to address unmet medical needs.

How Does KA Make Money?

• Develops and patents novel immunotherapies.
• Out-licenses or sells its therapies to larger pharmaceutical companies.
• Generates revenue through research grants and government contracts.
• Forms strategic partnerships to share development costs and risks.

What Industry Does KA Operate In?

Kineta, Inc. operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. Immunotherapy, Kineta's primary focus, is a rapidly growing segment within the biotechnology industry. Key competitors include both large pharmaceutical companies and smaller biotechnology firms developing similar immunotherapeutic approaches. Kineta's strategic partnerships and focus on specific therapeutic areas position it to potentially capture a share of this expanding market.

Who Are KA's Key Customers?

• Pharmaceutical companies seeking new drug candidates.
• Government agencies requiring biodefense solutions.
• Patients suffering from cancer and neurological disorders.
• Research institutions collaborating on drug development.

KA Valuation & Market Position

With a $7.05M market cap, Kineta, Inc. sits in the micro-cap segment of the market. Relative to its peer group, KA's quantitative score of 45/100 is below the peer average of 73/100.

FY2026 estForward Outlook

Wall Street analysts project Kineta, Inc. revenue of about $200.0M for fiscal 2026, with EPS near $0.00.

F-Score 3/9Financial Health

Kineta, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

ROE 26%Key Financial Metrics

Return on equity for Kineta, Inc. stands at 26.3%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -52.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -44.7%, the inverse of the P/E and a quick read on earnings relative to price.

KA Financials

KA Latest News

KA Analyst Consensus

KA MoonshotScore

Common Questions About KA (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources